Core Viewpoint - Optimi Health Corp. is implementing equity compensation and marketing initiatives to support its growth strategy and enhance market awareness [1] Equity Incentive Grants - The company has approved the grant of 850,000 stock options and 555,000 restricted share rights to directors, officers, employees, and key individuals [2] - The stock options are exercisable for five years at an exercise price of $0.50 per common share, while the restricted share rights will convert into common shares without additional consideration [3] Marketing and Sponsored Research Initiatives - Optimi has entered into a research sponsorship agreement with Diamond Equity Research LLC to provide independent research coverage, including an initiation report and financial valuation model [4] - Research coverage will be distributed through various financial and social media platforms such as FactSet, LinkedIn, Yahoo Finance, and Google Finance [5] Marketing and Investor Awareness Services - The company has engaged Native Ads Inc. for investor awareness and promotional services, with a digital media campaign set to begin in Q1 2026 and last up to 24 months [6] - A budget of up to US$350,000 has been approved for the digital advertising campaign aimed at increasing awareness of the company's MDMA and psilocybin products [7][8] Company Overview - Optimi Health Corp. is a GMP-compliant pharmaceutical drug manufacturer licensed by Health Canada, operating from two facilities in British Columbia [9]

Core Insights - Optimi Health Corp. is a leading producer of prescribed psychedelic treatments for mental health therapies, and it has been invited to present at the Sidoti Micro-Cap Virtual Conference on January 21-22, 2026 [1][4]. Company Overview - Optimi Health Corp. is a Health Canada-licensed and GMP compliant pharmaceutical manufacturer, producing validated MDMA and botanical psilocybin products from two facilities in British Columbia, each spanning 10,000 square feet [4]. - The company supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently available for prescription use in Australia and accessible in Canada through the Special Access Program [4]. Event Participation - CEO Dane Stevens will host virtual one-on-one meetings with institutional investors during the conference and will present on January 21, 2026, at 11:30 a.m. Eastern Time [2]. - Interested media and investors are invited to join the online presentation, with a recommendation to log in at least five minutes early for timely participation [2].

Core Insights - Optimi Health's psilocybin capsules have been included in Medibank's AUD $10 million psychotherapy program for Treatment-Resistant Depression (TRD) [2][3][4] - Medibank, Australia's largest private health insurer, previously funded MDMA-assisted therapy for PTSD and is now expanding its coverage to include psilocybin [4][6] - The inclusion of psilocybin reflects a strategic shift towards supporting innovative mental health therapies [6][7] Company Overview - Optimi Health Corp. is a Canadian GMP-compliant manufacturer of MDMA and psilocybin, licensed by Health Canada [3][9] - The company operates from two facilities in British Columbia and supplies active pharmaceutical ingredients and finished dosage forms [9][10] - Optimi's psilocybin capsules became available in Australia on September 3, 2025, under the Authorized Prescriber Scheme [6][10] Industry Context - The Medibank psychotherapy program is part of a broader AUD $50 million initiative aimed at improving mental health access and innovation over five years [6] - The growing acceptance of psychedelic medicines in insured mental health care indicates a shift in treatment paradigms for conditions like TRD and PTSD [7]

MDMA circulation sparks Electric Picnic warning https://t.co/vHqAyn8zbG ...

Allegations and Concerns - Allegations of misreporting serious adverse events, including suicidal behavior, during clinical trials [5] - Concerns about a "therapy cult" dynamic within Lykos, potentially indoctrinating therapists and participants [9] - Lykos's therapy model, based on Stanislav Grof's teachings, involves reenacting interpersonal trauma, raising ethical concerns [14] - Specific instances of therapists engaging in abusive practices, such as pinning down patients, are documented [15] Regulatory and Ethical Issues - Opposition to Lykos Therapeutics' MDMA-assisted therapy application for PTSD due to safety and efficacy concerns [3] - The FDA granted a request to extend the open public hearing to address concerns about Lykos's therapy [8] - The argument that Lykos's intervention heightens risks for patients by promoting boundary violations by therapists [18] - The advisory committee outcome sent a message of validation to people who have been hurt [19] Company Practices - Lykos's therapy is described as nondirective and empathetic, but this is misleading [12] - Lykos claims its therapy reduces the risk of assault, but the intervention directly contributed to sexual and physical assaults by therapists [13] - Lykos's training will ensure that boundaries are maintained, but its intervention actually heightens the risks for for patients by promoting boundary violations by therapists [18]

Core Viewpoint - Optimi Health Corp. has announced a non-brokered private placement of CAD$3.45 million through the issuance of unsecured convertible debentures and an extension of a secured term loan, aimed at enhancing its working capital and financial flexibility [1][3]. Group 1: Convertible Debentures - The company plans to issue 3,450 unsecured convertible debentures at a price of CAD$1,000 each, totaling gross proceeds of CAD$3,450,000 [1]. - The convertible debentures will have an interest rate of 15.0% per annum, payable quarterly, and will mature in 12 months, extendable for an additional 12 months [1][2]. - The conversion price for the debentures is set at $0.15, based on the closing price of the common shares prior to the subscription agreement [1][2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general working capital purposes [3]. - All securities issued will be subject to a hold period of four months and a day from the issuance date, in compliance with CSE rules [3]. Group 3: Related Party Transactions - The offering constitutes a related party transaction, involving the CEO and Chair of the Board as investors, with their respective holdings post-acquisition being 12.29% and 8.52% of the company [3]. - The company is relying on exemptions from certain valuation and minority shareholder approval requirements due to the fair market value of the insiders' participation not exceeding 25% of the company's market capitalization [3]. Group 4: Secured Term Loan - The company has extended a non-dilutive debt financing agreement for CAD$1,000,000, secured against its assets, with a new maturity date of April 30, 2026 [4][5]. - The loan bears an interest rate of 7.5% per annum, payable quarterly, and the company can repay the loan at any time with prior notice [5]. - As part of the loan extension, the company has granted 400,000 common share purchase warrants, exercisable at $0.25 per share for two years [5]. Group 5: Company Overview - Optimi Health Corp. is a Health Canada-licensed manufacturer of GMP-compliant natural psilocybin and MDMA, focusing on high-quality psychedelic products to support mental health therapies [6].